{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoP7evY4KDA","founded_year":1995,"lastupdate":"2023-01-04T00:00:00.000Z","update_date":"2023-01-04T00:00:00.000Z","lastModified":"Sep 17, 2020","confidence_score":76,"active":1,"confidence_score_reason":"product stage, sector, founding month, business model, video or image, funding rounds, markets","urlname":"recipharm","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"description_edited":0,"tag_line_edited":1,"phone":"+97289293840","registrar":"","biverification":"Yanina Wainscheinker","recentupdates":[{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-02-13 06:48:26.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-05 14:13:05.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-04 18:43:08.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-04 18:45:05.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-01-25 08:13:17.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-04 18:43:08.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-01-25 08:13:17.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-22 06:41:36.000000","last_name":"Levin","first_name":"Eran"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 10:12:25.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 10:08:22.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:53:03.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:53:03.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:50:53.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:50:53.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:47:51.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:44:41.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:44:05.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:38:59.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:38:59.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:38:59.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:38:59.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:38:59.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:38:59.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:38:59.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 10:07:13.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 10:07:13.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 10:07:13.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:45:57.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:46:29.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:54:11.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:44:15.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"genys30@yahoo.com","source":"Manual","datetime":"2018-02-05 16:06:39.000000","last_name":"Sotnik-Talisman","first_name":"Jenny"},{"email":"genys30@yahoo.com","source":"Manual","datetime":"2018-02-05 16:06:39.000000","last_name":"Sotnik-Talisman","first_name":"Jenny"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:48:47.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:48:47.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 10:10:41.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:49:02.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:47:14.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:47:14.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"genys30@yahoo.com","source":"Manual","datetime":"2018-02-05 16:06:22.000000","last_name":"Sotnik-Talisman","first_name":"Jenny"},{"email":"genys30@yahoo.com","source":"Manual","datetime":"2018-02-05 16:06:22.000000","last_name":"Sotnik-Talisman","first_name":"Jenny"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:42:15.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:49:03.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:42:29.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:46:17.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:49:04.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:49:36.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:48:07.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:41:25.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-05 09:41:25.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"sylviakachalsky@gmail.com","source":"Manual","datetime":"2020-09-17 07:05:33.000000","last_name":"Kachalsky","first_name":"Sylvia"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2020-09-14 17:51:24.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2020-09-14 17:53:49.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2020-09-14 17:53:49.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2020-09-14 17:53:49.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"sylviakachalsky@gmail.com","source":"Manual","datetime":"2020-09-17 06:46:04.000000","last_name":"Kachalsky","first_name":"Sylvia"},{"email":"sylviakachalsky@gmail.com","source":"Manual","datetime":"2020-09-17 07:05:33.000000","last_name":"Kachalsky","first_name":"Sylvia"},{"email":"sylviakachalsky@gmail.com","source":"Manual","datetime":"2020-09-17 07:05:30.000000","last_name":"Kachalsky","first_name":"Sylvia"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2020-09-14 17:53:51.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2019-03-20 15:51:50.000000","last_name":"McCandless","first_name":"Katie"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2019-03-20 15:51:50.000000","last_name":"McCandless","first_name":"Katie"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2019-03-20 15:51:50.000000","last_name":"McCandless","first_name":"Katie"},{"email":"sylviakachalsky@gmail.com","source":"Manual","datetime":"2020-09-17 07:05:35.000000","last_name":"Kachalsky","first_name":"Sylvia"},{"email":"sylviakachalsky@gmail.com","source":"Manual","datetime":"2020-09-17 07:05:35.000000","last_name":"Kachalsky","first_name":"Sylvia"},{"email":"sylviakachalsky@gmail.com","source":"Manual","datetime":"2020-09-17 07:05:35.000000","last_name":"Kachalsky","first_name":"Sylvia"},{"email":"sylviakachalsky@gmail.com","source":"Manual","datetime":"2020-09-17 07:05:35.000000","last_name":"Kachalsky","first_name":"Sylvia"},{"email":"sylviakachalsky@gmail.com","source":"Manual","datetime":"2020-09-17 07:05:35.000000","last_name":"Kachalsky","first_name":"Sylvia"},{"email":"sylviakachalsky@gmail.com","source":"Manual","datetime":"2020-09-17 07:05:35.000000","last_name":"Kachalsky","first_name":"Sylvia"},{"email":"sylviakachalsky@gmail.com","source":"Manual","datetime":"2020-09-17 07:05:32.000000","last_name":"Kachalsky","first_name":"Sylvia"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2020-09-14 17:54:41.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"sylviakachalsky@gmail.com","source":"Manual","datetime":"2020-09-17 07:05:31.000000","last_name":"Kachalsky","first_name":"Sylvia"},{"email":"sylviakachalsky@gmail.com","source":"Manual","datetime":"2020-09-17 07:05:34.000000","last_name":"Kachalsky","first_name":"Sylvia"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2019-04-08 14:09:13.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2019-04-08 14:09:13.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2019-04-08 14:09:13.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"sylviakachalsky@gmail.com","source":"Manual","datetime":"2020-09-17 07:02:49.000000","last_name":"Kachalsky","first_name":"Sylvia"},{"email":"sylviakachalsky@gmail.com","source":"Manual","datetime":"2020-09-17 07:05:31.000000","last_name":"Kachalsky","first_name":"Sylvia"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2020-09-14 17:43:31.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2020-09-14 17:47:09.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-05 15:02:10.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-04 18:43:08.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2025-02-06 12:42:57.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-04 18:47:05.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-01-25 16:35:30.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Automatic","datetime":"2023-01-04 18:43:39.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-08-07 06:12:58.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-05 14:49:40.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-04 18:47:05.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-03-20 06:45:40.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-08-07 05:10:16.000000","last_name":"Levin","first_name":"Eran"}],"sectorverify":null,"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMGgoMMJDA","fullname":"Yanina Wainscheinker"},"biverifydate":"2020-09-14T00:00:00.000Z","crunchbaseid":"recipharm","lastupdator":"Maor Perlov","lastupdator_email":"maor.perlov@sncentral.org","creator":"Yamila Silbert","creator_email":"yamila.urwicz@gmail.com","createdate":"2018-02-05T00:00:00.000Z","lastupdatedate":"2023-01-04","hide_reason":null,"hide_reason_data":null,"logokey":"$myZjE5OO7edgiDijqkPxfIjrWSP4RlnBbI1Ih8lzgrWJLzmK44SOYL","name":"Recipharm","israeliacquisitions":0,"forbesranking":null,"investmentarm":null,"investmentarmname":null,"hubname":null,"acquired_amount":null,"acquired_by":null,"acquired_country":null,"acquired_month":null,"acquired_year":null,"type":"Multinational","formernames":["OnTarget Chemistry"],"alternativenames":[""],"country":"Sweden","inisraelsince":"5/2015","inisraelsincemonth":"5","isisraeli":0,"marketcapital":16032000000,"marketcapitaldate":"2020-01-01T00:00:00.000Z","oneliner":"Pharmaceuticals","website":"https://www.recipharm.com","employees":"11-50","employees_exact":12,"employees_overall":"1,001-5,000","employees_overall_exact":3180,"sociallinks":{"twitter":"https://twitter.com/recipharmab","youtube":"https://www.youtube.com/channel/UCr-bw7pCCkYZfeImOwTfNRg","facebook":"https://www.facebook.com/recipharm","linkedin":"https://www.linkedin.com/company/52937","instagram":""},"social":["https://www.facebook.com/recipharm","https://www.youtube.com/channel/UCr-bw7pCCkYZfeImOwTfNRg","https://www.linkedin.com/company/52937","https://twitter.com/recipharmab"],"flattenedsociallinks":"https://www.facebook.com/recipharm|https://www.youtube.com/channel/UCr-bw7pCCkYZfeImOwTfNRg|https://www.linkedin.com/company/52937|https://twitter.com/recipharmab","apps":{"appstore":"","googleplay":""},"investmentstage":[],"about":"Recipharm AB, is providing contract pharmaceutical development and manufacturing services. The company supplies several hundred different products in a variety of dosage forms including solid dose, semi solids, steriles (liquids and freeze dried), beta-lactams, hormones, dry powder inhalers, synthetic cannabinoids, and granulates.\n\nRecipharm  Israel is one of Recipharm's development facilities.  Withs extensive experience in medicinal chemistry equipped with state of the art chemical facility's we can support small and large companies seeking chemical expertise.  The offerings include a wide array of services in chemical synthesis, optimisation and analysis including some very demanding specialities such as synthetic cannabinoids and antibiotics. \n\nThe company also offers bio-analytical and other pre-clinical services.","founded":"1995","team":[{"name":"Sylvia Kachalsky","email":"sylviakachalsky@gmail.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4LHh2qgLDA","bounced":false,"claimed":1,"founder":0,"urlname":"sylvia-kachalsky","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICg_rXXuAoM","position":"CEO at Recipharm Israel","last_name":"Kachalsky","claimtoken":"d367f4c9daa888c3210cb77dd15a435c7c4913bb6267ebc001e804b44c0fef81","first_name":"Sylvia","picturekey":"$V651wJNBVJst1hQFf8kFYr0PLQzoSXcyJtK3RmAyb1WB6FmN0lQYhn","claimeddate":"2020-09-17","linkedinurl":null,"unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2020-09-17 06:46:05.000000","initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$V651wJNBVJst1hQFf8kFYr0PLQzoSXcyJtK3RmAyb1WB6FmN0lQYhn","linkedin-display":"none","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Helen  Domeshek","email":"helen.domeshek@recipharm.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4IW_18cJDA","bounced":false,"claimed":0,"founder":0,"urlname":"helen-domeshek","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDghfi_tQgM","position":"Business Development","last_name":"Domeshek","claimtoken":"f9dc317ed45b35f88d82b368ad002b2543a54a1410ef1c18710be57a8348e8de","first_name":"Helen ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/helen-domeshek-phd-7a563a3b/","unsubscribed":true,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2020-09-17 06:59:44.000000","initials":"HD","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Efrat Levin","email":"efrat.levin@recipharm.com","phone":"0523477088","gender":"Unknown","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4Nm7hqUJDA","bounced":false,"claimed":0,"founder":0,"urlname":"efrat-levin","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg5bj6nwoM","position":"Commercial Project Manager","last_name":"Levin","claimtoken":"69081590c392bca3a404b2840b5e10d2f6c6274bdcaa8933a490692ab561fff4","first_name":"Efrat","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/efrat-levin-6b3917b1/","unsubscribed":true,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2020-09-17 07:02:50.000000","initials":"EL","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"portfolio":[],"exits":[],"mediagallery":[],"affiliatedOrganizations":null,"address":{"israeli":[{"id":"a3177e3a-53c2-401e-90de-1d0e1f7ffc04","city":"Yavne","type":["R&D","Sales"],"address":"Nachal Snir St 5, Yavne, Israel","placeid":null,"notactive":0,"openeddate":"2015-05-01","registrarid":"515254944","firstrdcenter":0,"registrarname":"Recipharm Israel Ltd"}],"officesabroad":null},"headquarter_address":"Stockholm, Sweden","news":[{"id":"1b5fd838-f5ca-437f-9272-b3ab57e8eac1","date":"Jul 9, 2020","link":"https://www.proactiveinvestors.com/companies/news/923829/innocan-pharma-collaborating-with-recipharm-in-israel-to-synthesize-and-analyze-cannabinoid-loaded-exosomes-923829.html","source":"www.proactiveinvestors.com","visible":1,"analysis":{"tags":"Partnership, Research","company":"InnoCan Pharma","layoffs":null,"summary":"InnoCan Pharma is partnering with Recipharm, a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry, to synthesize and analyze cannabinoid-loaded exosomes. Exosomes are extracellular vesicles that play a crucial role in cell-to-cell communication and are being explored as a means of drug delivery. The partnership will allow InnoCan to focus on exosome technology production/loading technology while Recipharm will work on the cannabinoids. The project has the potential to be applied to a wide range of indications.","partners":["Recipharm"],"customers":null,"investors":null,"confidence":8,"key_topics":["Exosomes","Drug Delivery","Cannabinoids","Recipharm","Research"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"QUpFCHul2QQbWqnneaEanhj5aU5JZz1qeoOEUyKQsmCpu7NLhDMriq","news_summary":"InnoCan Pharma collaborating with Recipharm in Israel to synthesize and analyze cannabinoid-loaded exosomes","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"f1e15414-fbf6-427b-a14b-a773575b0719","date":"May 15, 2018","link":"https://dcatvci.org/supplier-news/5430-cdmo-recipharm-expands-capabilities-in-israel","source":"dcatvci.org","visible":1,"analysis":{"tags":"partnership","company":"Recipharm","layoffs":null,"summary":"Recipharm has partnered with Hadasit Medical Research Services and Development to offer combined clinical, biological, and chemical services. Hadasit provides specialist services, including in vitro analysis, access to human samples, in vivo models, and clinical trials. This partnership is part of Recipharms growth plans.","partners":["Hadasit Medical Research Services and Development"],"customers":null,"investors":null,"confidence":8,"key_topics":["Recipharm","Hadasit Medical Research Services and Development","clinical services","biological services","chemical services"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"UbLEuxeISJXh3xKOLRWLhGItwXvNhVsLze1FB4bRn0j37dMRCM5DEr","news_summary":"CDMO Recipharm Expands Capabilities in Israel - DCAT Value Chain Insights","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"extensions":null,"events":null,"hide_reasons":[{"id":"75T5aG1f0dpqYFonup40lXNjO046zUH82TaHW1TAiIMf9aYAsSOl0d","reason":"No relevant activity"},{"id":"7KVi9S7qqUtO0WCsFclwqBEZluejfNYqWC1Uhx0tPHtDxtvxPPaCPH","reason":"No longer active"},{"id":"hoyKAmu4YJEHmhtLwCdeFldSnDwaVbPXOnH0RA9hKHCzAcHO6OOrXd","reason":"Pending approval"},{"id":"TC54H7CXyKO8GmPECkbyKJf8n34r70JlfJTJHfo85exRpLaKI1Efs9","reason":"Pending approval - External entity"}],"timeline":[],"techcommunityinvolvement":null,"tags":["medical-technologies","pharmaceuticals","biotechnology","diagnostics","medical-devices","cannabis","agtech","drug-development"],"investments":[],"funds":[],"databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"1,001-5,000","fundingtype":"Multinational","parsedName":"Recipharm","logourl":"https://storage.googleapis.com/clean-finder-353810/$myZjE5OO7edgiDijqkPxfIjrWSP4RlnBbI1Ih8lzgrWJLzmK44SOYL","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$myZjE5OO7edgiDijqkPxfIjrWSP4RlnBbI1Ih8lzgrWJLzmK44SOYL","teamMembersNumber":3,"nationality":"Foreign","communityinvolvement":[],"popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none"},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}